Evidence map›Paper›PMID 39451690›Full record

ReviewBiosensors2024

The Evolution of Illicit-Drug Detection: From Conventional Approaches to Cutting-Edge Immunosensors-A Comprehensive Review.

Nigar Anzar, Shariq Suleman, Yashda Singh, Supriya Kumari, Suhel Parvez, Roberto Pilloton, Jagriti Narang

Abstract readReview
In one paragraph

Review in Biosensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nigar AnzarDepartment of Biotechnology, School of Chemical and Life Science, Jamia Hamdard University, New Delhi 110062, India.ORCID 0009-0009-6234-6369
Shariq SulemanDepartment of Biotechnology, School of Chemical and Life Science, Jamia Hamdard University, New Delhi 110062, India.
Yashda SinghDepartment of Biotechnology, School of Chemical and Life Science, Jamia Hamdard University, New Delhi 110062, India.
Supriya KumariDepartment of Biotechnology, School of Chemical and Life Science, Jamia Hamdard University, New Delhi 110062, India.
Suhel ParvezDepartment of Toxicology, School of Chemical and Life Science, Jamia Hamdard University, New Delhi 110062, India.ORCID 0000-0002-6318-6506
Roberto PillotonNational Research Council, Department of Chemical Sciences and Materials Technology, Institute of Crystallography, 00015 Rome, Italy.ORCID 0000-0002-5329-110X
Jagriti NarangDepartment of Biotechnology, School of Chemical and Life Science, Jamia Hamdard University, New Delhi 110062, India.

Funding

Jamia Hamdard, Department of Biotechnology (DBT) BT/PR31594/MED/32/738/2020
6 · The paper itself

Abstract

The increasing use of illicit drugs has become a major global concern. Illicit drugs interact with the brain and the body altering an individual's mood and behavior. As the substance-of-abuse (SOA) crisis continues to spread across the world, in order to reduce trafficking and unlawful activity, it is important to use point-of-care devices like biosensors. Currently, there are certain conventional detection methods, which include gas chromatography (GC), mass spectrometry (MS), surface ionization, surface-enhanced Raman spectroscopy (SERS), surface plasmon resonance (SPR), electrochemiluminescence (ECL), high-performance liquid chromatography (HPLC), etc., for the detection of abused drugs. These methods have the advantage of high accuracy and sensitivity but are generally laborious, expensive, and require trained operators, along with high sample requirements, and they are not suitable for on-site drug detection scenarios. As a result, there is an urgent need for point-of-care technologies for a variety of drugs that can replace conventional techniques, such as a biosensor, specifically an immunosensor. An immunosensor is an analytical device that integrates an antibody-based recognition element with a transducer to detect specific molecules (antigens). In an immunosensor, the highly selective antigen-antibody interaction is used to identify and quantify the target analyte. The binding event between the antibody and antigen is converted by the transducer into a measurable signal, such as electrical, optical, or electrochemical, which corresponds to the presence and concentration of the analyte in the sample. This paper provides a comprehensive overview of various illicit drugs, the conventional methods employed for their detection, and the advantages of immunosensors over conventional techniques. It highlights the critical need for on-site detection and explores emerging point-of-care testing methods. The paper also outlines future research goals in this field, emphasizing the potential of advanced technologies to enhance the accuracy, efficiency, and convenience of drug detection.

Indexed as

Biosensing TechniquesIllicit DrugsElectrochemical TechniquesHumansImmunoassayPoint-of-Care SystemsSpectrum Analysis, RamanSubstance Abuse DetectionSurface Plasmon ResonanceIllicit Drugsconventional methodsillicit drugsimmunosensorspoint-of-care testing methods

Identifiers

PMID39451690
PMCPMC11506482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.